Professor
Keith Wailoo, Ph.D., is an historian of medicine and the biomedical
sciences. In July 2001, he joined the
faculty of Rutgers University as Professor of History jointly appointed to the
Institute for Health, Health Care Policy and Aging Research. Previously, he served nine years on the
faculty at the University of North Carolina at Chapel Hill, and one year as
visiting professor of the History of Science and Afro-American Studies at
Harvard University. He received his
Ph.D. in the History and Sociology of Science in 1992 from the University of
Pennsylvania.
Professor Wailoo’s first book, Drawing Blood: Technology and Disease
Identity in Twentieth-Century America (Johns Hopkins University Press,
1997) – exploring the benefits, pitfalls, and complexities associated with
technology in 20th century hematology and medicine – received the
1997 Arthur Viseltear Award from the American Public Health Association. His most recent book, Dying in the City of the Blues: Sickle Cell Anemia and the Politics of
Race and Health (University of North Carolina Press, 2001) examines the
disease’s early 20th century invisibility, its gradual rise to
clinical, scientific, and political prominence, and the changing
socio-political significance into the era of managed care.
Professor Wailoo has taught courses on a wide range of topics, including: Pain, Medicine, and Society in America; Medicine, the Family, and the Politics of Child Health; Disease in Historical Perspective; ‘Racial Health’ and the American South; Genetics, Race, and Medicine; The Politics of Patienthood; and Medicine and Society in America.
In 1999, he received the prestigious James S. McDonnell Centennial Fellowship in the History of Science – a $1,000,000 award to examine the history of cancer, immunology, genetics, and pain in the biomedical sciences and in 20th century society. He has also received awards and grants from the National Science Foundation, the National Center for Human Genome Research (Ethical, Legal, and Social Issues Program), and the Burroughs Wellcome Fund.